Alex V. Stabler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex V. Stabler has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Allyson Young
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center
2 shared publicationsChun Feng
Department of Pharmacy Quality-Regulatory, The University of Texas MD Anderson Cancer Center
2 shared publications- Hyunsoo Hwang
Department of Biostatistics, The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publications - Jovan Borjan
Division of Pharmacy, The University of Texas MD Anderson Cancer Center
2 shared publications Nancy N. Vuong
Division of Pharmacy, The University of Texas MD Anderson Cancer Center
2 shared publications- Samuel Shelburne
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center
2 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0278125
Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia
Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC; meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within 1 year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI based on organism. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio [OR], 7.41; P = 0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio [HR], 1.055; P = 0.016). Genomic data suggest beta-lactamase amplification and outer membrane porin mutations may be potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors. IMPORTANCE: Non-carbapenemase-producing (non-CP) carbapenem-resistant Enterobacterales (CRE) are an important classification of CRE. Increasing rates of non-CP CRE that display carbapenem susceptibility discordance (CSD-E; ertapenem-resistant, meropenem susceptible) have been observed globally and at our institution. Our article aims to characterize risk factors, including cumulative antibiotic exposure, leading to carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infection (BSI) in immunocompromised patients with a history of Enterobacterales BSI. In addition, we analyzed paired whole-genome sequencing data to assess antimicrobial gene content for mechanistic rationales supporting our clinical findings. The risk factors for CSD-E development identified in this study require further validation in multicenter cohorts.
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0278125
Open AccessCumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia
Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC; meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within 1 year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI based on organism. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio [OR], 7.41; P = 0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio [HR], 1.055; P = 0.016). Genomic data suggest beta-lactamase amplification and outer membrane porin mutations may be potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors. IMPORTANCE: Non-carbapenemase-producing (non-CP) carbapenem-resistant Enterobacterales (CRE) are an important classification of CRE. Increasing rates of non-CP CRE that display carbapenem susceptibility discordance (CSD-E; ertapenem-resistant, meropenem susceptible) have been observed globally and at our institution. Our article aims to characterize risk factors, including cumulative antibiotic exposure, leading to carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infection (BSI) in immunocompromised patients with a history of Enterobacterales BSI. In addition, we analyzed paired whole-genome sequencing data to assess antimicrobial gene content for mechanistic rationales supporting our clinical findings. The risk factors for CSD-E development identified in this study require further validation in multicenter cohorts.
- Open Access
Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia
Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC;meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within one year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio[OR],7.41;p=0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio[HR],1.055;p=0.016). Genomic data revealed beta-lactamase amplification and outer membrane porin mutations as potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors.
Open AccessCumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia
Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC;meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within one year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio[OR],7.41;p=0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio[HR],1.055;p=0.016). Genomic data revealed beta-lactamase amplification and outer membrane porin mutations as potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors.
- 6 February 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (5) , 473-485
Significant Publications on Infectious Diseases Pharmacotherapy in 2023
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2023. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2023. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. Out of the 31 articles nominated by HIDN members, 22 pertained to general ID pharmacotherapy, and 9 pertained to HIV/AIDS pharmacotherapy. To aid selection of the most notable articles of 2023, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 118 recorded votes for the top 10 general ID pharmacotherapy articles and 55 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Advances in antimicrobial stewardship and infectious disease states continue to occur. Sustained growth in the publication of ID-related articles over the past year contributed to this review’s aim to aid clinicians in remaining current on potentially practice-changing ID pharmacotherapy publications from 2023. This review provides a summary of recently published ID literature, including emphasis on antimicrobial stewardship, appropriate treatment durations, new antimicrobials, and drug-resistant organisms.
- 6 February 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (5) , 473-485
Significant Publications on Infectious Diseases Pharmacotherapy in 2023
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2023. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2023. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. Out of the 31 articles nominated by HIDN members, 22 pertained to general ID pharmacotherapy, and 9 pertained to HIV/AIDS pharmacotherapy. To aid selection of the most notable articles of 2023, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 118 recorded votes for the top 10 general ID pharmacotherapy articles and 55 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Advances in antimicrobial stewardship and infectious disease states continue to occur. Sustained growth in the publication of ID-related articles over the past year contributed to this review’s aim to aid clinicians in remaining current on potentially practice-changing ID pharmacotherapy publications from 2023. This review provides a summary of recently published ID literature, including emphasis on antimicrobial stewardship, appropriate treatment durations, new antimicrobials, and drug-resistant organisms.
- 30 August 2011
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 71 (08) , M_5
The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer
Introduction: Recent studies have shown that the detection of circulating tumor cells (CTC) pre- and postoperatively in the peripheral blood of primary breast cancer patients may be an indicator for poor survival. This study aimed to investigate the influence of removal of the primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Methods: 209 primary breast cancer patients could be included into this analysis. Blood sampling was performed both pre- and postoperatively. The blood specimens were immunomagnetically enriched using AdnaTest BreastCancerSelect within 4 hours after blood withdrawal, followed by RNA isolation and subsequent gene expression analysis by reverse transcription and multiplex-PCR using AdnaTest BreastCancerDetect. Three breast-cancer-associated tumor markers and two hormone receptor genes were amplified: GA733–2, Muc-1, Her-2, ER, PR. In addition, bone marrow (BM) status was intraoperatively determined. Results: Forty-three of 209 patients (21%) had pre- and/or postoperatively circulating tumor cells. The positivity rates after surgery were higher but did not differ significantly (12% pre- and 16% postoperatively). Disseminated tumor cells in BM were seen in 32 of 209 cases (15%). Patients with positive BM status had significantly higher CTC positivity rates both pre- and postoperatively compared to those with negative BM status. The most common CTC phenotype was triple negative (24 patients) followed by HER2+/ER-/PR- subtype (10) and ER and/or PR positive (9). Interestingly, 41 of 43 primary tumors (95%) were ER and PR positive. Removal of the primary tumor did not alter the phenotype of CTC. Conclusions: Surgery does not significantly influence the tumor cell load in the blood stream. CTC phenotype before and after the surgery generally remains identical but may differ from that of the primary tumor.
- 30 August 2011
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 71 (08) , M_5
The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer
Introduction: Recent studies have shown that the detection of circulating tumor cells (CTC) pre- and postoperatively in the peripheral blood of primary breast cancer patients may be an indicator for poor survival. This study aimed to investigate the influence of removal of the primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Methods: 209 primary breast cancer patients could be included into this analysis. Blood sampling was performed both pre- and postoperatively. The blood specimens were immunomagnetically enriched using AdnaTest BreastCancerSelect within 4 hours after blood withdrawal, followed by RNA isolation and subsequent gene expression analysis by reverse transcription and multiplex-PCR using AdnaTest BreastCancerDetect. Three breast-cancer-associated tumor markers and two hormone receptor genes were amplified: GA733–2, Muc-1, Her-2, ER, PR. In addition, bone marrow (BM) status was intraoperatively determined. Results: Forty-three of 209 patients (21%) had pre- and/or postoperatively circulating tumor cells. The positivity rates after surgery were higher but did not differ significantly (12% pre- and 16% postoperatively). Disseminated tumor cells in BM were seen in 32 of 209 cases (15%). Patients with positive BM status had significantly higher CTC positivity rates both pre- and postoperatively compared to those with negative BM status. The most common CTC phenotype was triple negative (24 patients) followed by HER2+/ER-/PR- subtype (10) and ER and/or PR positive (9). Interestingly, 41 of 43 primary tumors (95%) were ER and PR positive. Removal of the primary tumor did not alter the phenotype of CTC. Conclusions: Surgery does not significantly influence the tumor cell load in the blood stream. CTC phenotype before and after the surgery generally remains identical but may differ from that of the primary tumor.